Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
about
Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysisThe asthma-COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease?Acute exacerbation of COPDClinical Question: In adults with COPD does roflumilast reduce the frequency of exacerbations compDared to standard therapies aIone?Roflumilast: a review of its use in the treatment of COPDA rational approach to single, dual and triple therapy in COPDA re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary diseaseCan roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysisPharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewTreatment of patients with COPD and recurrent exacerbations: the role of infection and inflammationPrevention of COPD exacerbations: medications and other controversiesDrug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study.A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Quantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPDThe phenotype of concurrent chronic bronchitis and frequent exacerbations in patients with severe COPD attending Swedish secondary care units.A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerAdditive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cellsFunctional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMACurrent concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.Determinants for changing the treatment of COPD: a regression analysis from a clinical audit.Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models.Efficacy and Safety of Roflumilast in Korean Patients with COPD.The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD ExacerbationBiomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD.COPD, stage and treatment in a large outpatient clinic.Roflumilast: A Review in COPD.Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.Update in Chronic Obstructive Pulmonary Disease 2014.GOLD Stage and Treatment in COPD: A 500 Patient Point Prevalence StudyEmerging pharmaceutical therapies for COPD.Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases.Inhaled corticosteroids and the increased risk of pneumonia: what's new? A 2015 updated review.Treatment options for moderate-to-very severe chronic obstructive pulmonary disease.Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators.Prediction and prevention of exacerbations and mortality in patients with COPD.
P2860
Q26740229-F628BD8E-2F3A-48BA-810E-836A16962BDCQ26745760-22B66FE3-51A7-4339-B6E2-F147ACC2873BQ26749302-C1C6EFD4-DC34-4098-88BB-B56C3DB621F8Q26750569-5387650B-2CF2-4810-8E44-1F321D66FF7BQ26770501-B1736E11-8D3C-47BC-B28D-CE880FE26A93Q26776477-ACCF18E1-21BE-4341-87F1-964248FE4931Q26801661-B4185EE2-9485-4DE0-8595-E5A602EC1139Q28070108-918F9BCB-C66B-4201-8F75-BE052E1842B2Q28070274-2A0F9076-6799-49EC-9492-26C3EB8EF83CQ28071694-BAB02952-BA59-44D8-9199-C8A93BDDAF52Q28596774-A3D90096-21CA-444B-B763-3EF78EA54573Q30249747-D28C52B4-F575-4CBB-B9FB-AA3430FC28D7Q33768773-7D455871-D270-412D-861F-FC194F501204Q33838209-1D673767-9D78-46E4-86A8-AB14711F36F8Q34550471-40E7833A-8B45-4368-959B-10BB30ECE9B5Q35681671-A5019DCA-821F-410E-BE8A-B02CFD92B251Q36240664-BEBD213F-277C-4492-862E-A25707AF06EEQ36272434-63A4EE97-AE02-4768-94A4-BC99D6B20D3EQ36350128-4F057022-FC5F-412D-B518-20211A9C5A51Q36503797-9BA7713C-B226-41EB-AD63-A1E73324A249Q36557694-59B3BCE6-847A-4624-AD5C-B8A5A0F8F4C4Q36907742-0EF3CB80-5062-412B-B103-3B658734DC23Q36981197-576A0EAA-6D96-42BA-B41A-2C3651767E7DQ37054398-2C86BCDB-7344-4CC0-A4F6-AE9626B4BADEQ37110198-972F090A-A369-42B3-AE13-BC8DC75EE66DQ37128138-ED0FF897-A3D6-4DD4-ACEA-375593577BC3Q37197253-732690B5-52FE-43FA-8D26-9987E2EA5E3DQ37217235-2081A29B-B085-466D-96EA-4DB4C26EA29DQ37595806-F7B890DF-BD03-4631-AA4B-1287280B7097Q37669652-6EF9A5E8-2564-4007-A6C3-B7FA02B44F5CQ38580536-D289168D-142E-442C-89EC-DB8E699944ADQ38595360-33A41220-3977-44E8-88B4-4240C49E675DQ38620368-A4879460-90D5-41F4-938D-9F47A65E8D8DQ38636421-A1D404DB-249A-480F-9B87-62191FD20063Q38645203-B2FBEFBA-6EE8-4112-9BD3-C04AFAEC6574Q38681962-4DDDD4C5-C1C1-4D6F-8008-EA035CF4B6FEQ38740312-F0EAAFF1-1BDF-4FA5-B44E-ACCBB55553CDQ38740756-546C3C3D-5429-4D04-A77A-0D8435BFC9E2Q38751226-0A06B588-0EB8-43C4-BB83-3144D5187035Q38823010-A76702B1-BCD2-48A8-AC83-82D94DE2D43B
P2860
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Effect of roflumilast on exace ...... e randomised controlled trial.
@en
Effect of roflumilast on exace ...... trolled by combination therapy
@nl
type
label
Effect of roflumilast on exace ...... e randomised controlled trial.
@en
Effect of roflumilast on exace ...... trolled by combination therapy
@nl
prefLabel
Effect of roflumilast on exace ...... e randomised controlled trial.
@en
Effect of roflumilast on exace ...... trolled by combination therapy
@nl
P2093
P1433
P1476
Effect of roflumilast on exace ...... e randomised controlled trial.
@en
P2093
Fernando J Martinez
Klaus F Rabe
Manja Brose
Peter M A Calverley
Udo-Michael Goehring
P304
P356
10.1016/S0140-6736(14)62410-7
P407
P577
2015-02-13T00:00:00Z